Table 2 Coexpression of HER-2/neu and p53 in relation to clinicopathological parameters of breast carcinoma

Histological type

Ductal Carcinoma

12

(19.35%)

20

(32.25%)

11

(17.45%)

19

(30.65%)

62

(88.57%)

Lobular Carcinoma

1

(12.50%)

0

(0%)

1

(12.50%)

6

(75%)

8

(11.43%)

R > 0.3

Tumor grade

Well-moderately differentiated

(I and II)

1

(7.14%)

6

(42.86%)

1

(7.14%)

6

(42.86%)

2

(2.86%)

Poorly differentiated (III)

12

(21.43%)

14

(25%)

11

(19.64%)

19

(33.93%)

56

(80%)

R < 0.3

Tumor size

Tis

2

(50%)

2

(50%)

0

(0%)

0

(0%)

4

(5.71%)

T1

0

(0%)

2

(28.57%)

2

(28.57%)

3

(42.86%)

7

(10%)

T2

2

(5.26%)

11

(28.94%)

4

(10.53%)

21

(55.27%)

38

(54.29%)

T3

8

(42.12%)

5

(26.31%)

6

(31.57%)

0

(0%)

19

(27.14%)

T4

1

(50%)

0

(0%)

0

(0%)

1

(50%)

2

(2.86%)

R > 0.3

Axillary lymph nodes

Node +ve

breast cancer

10

(34.49%)

9

(31.03%)

7

(24.14%)

3

(10.34%)

29

(51.79%)

Node-ve

breast cancer

2

(7.41%)

4

(14.81%)

5

(18.52%)

16

(59.26%)

27

(48.21%)

R < 0.3

Age of the patient

< 35 years

8

(4211%)

4

(21.05%)

0

(0%)

7

(36.84%)

19

(27.14%)

> 35years

5

(9.81%)

16

(31.37%)

12

(23.53%)

18

(35.29%)

51

(72.86%)

R > -0.3

Tumor recurrence

Primary

4

(7.84%)

13

(25.49%)

9

(17.65%)

25

(49.02%)

51

(72.86%)

Recurrent

9

(47.37%)

7

(36.84%)

3

(15.79%)

0

(0%)

19

(27.14%)

Total

13

(18.57%)

20

(28.57%)

12

(17.14%)

25

(35.71%)

70

(100%)

R > 0.3